Registration is open for the 9th Annual Biosimilars & Biobetters
Forecasting the next wave of biosimilars to ensure optimal market commercialisation
Sponsored by Impact Medical Education
The SMi Group are thrilled to present the 9th annual conference on Biosimilars & Biobetters, taking place on 26th & 27th September in Central London, UK. Following the success of our previous events in both London and the US, Biosimilars and Biobetters UK 2018, SMi deliver a stellar speaker line-up and bring together a global audience of biosimilar experts to discuss the latest developments and future of the rapidly evolving and expanding biosimilars market.
After over a decade, the biosimilars industry is finally reaching a stage where key stakeholders understand and accept biosimilars. This is reflected in more tolerant legislation and an increased uptake of biosimilars across the globe.
We are now entering a very exciting time, for over the next few years several originator patents are expiring, and we will see the next few waves of biosimilars enter the market. Will the biosimilar be a successful contender and spark a competitive environment or the originator dominate? Have we done enough to convince the payer, prescriber and patient to switch?
Join us to hear experiences of key opinion leaders and evaluate market access, opportunities and commercialisation strategies with industry-thought experts.
This event is CPD accredited. #SMiBioSim
PLUS TWO INTERACTIVE HALF-DAY PRE-CONFERENCE WORKSHOPS
Tuesday 25th September 2018, Copthorne Tara Hotel, Central London, UK
08.30 – 12.30 – A: Global Development of Biosimilars: A Refresher
Workshop Leader: Michel Mikhail, Global Expert in Biosimilars
13.30 – 17.30 – B: Value Based Agreements with Biosimilars: Architecture of Value Based Agreements
Workshop Leader: Omar Ali, Visiting Lecturer Value Based Pricing, University of Portsmouth & Former Adviser, NICE
WHO SHOULD ATTEND
Chief Executives, Vice Presidents, Executive Directors, Directors, Heads, Managers and Specialists from the following, but not limited to, sectors should attend:
- Biosimilars / Biologics
- Research and Development
- Legal Affairs
- Intellectual Property
- Regulatory Compliance
- Quality affairs and control
- Pharmacovigilance, Drug Safety and Risk Management
- Business Development
- Marketing and sales
For the updated brochure and to register your place – please visit www.biosimilars-europe.com/pharmaphorum